A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of Talquetamab, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04586426 by Janssen Research & Development, LLC, with 228 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-03-18. Interventions recorded: Talquetamab, Teclistamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Teclistamab, Johnson & Johnson, Multiple myeloma.
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares Talquetamab, Teclistamab, Multiple myeloma.